Genmab — Marts 2021
-
IV administration - det bliver spændende at se, om det er en seriøs konkurrencefordel
-
Ved vi egentlig, om Novartis er begyndt at kræve penge for Kesimpta?
-
Og gad vide, hvordan det egenlig fungerer. De amerikanske sygekasser kan ikke være specielt interesserede i gratis produkter
-
"Sales of Kesimpta notched just $14 million in the fourth quarter, but Novartis executives told reporters in January that the slow start doesn't change its overall expectations for the med—it's still anticipating a market share grab of up to 40%.
" https://www.fiercepharma.com/marketing/novartis-study-nurses-and-ms-patients-give-thumbs-up-to-kesimpta-for-ease-use -
Thx EL
-
Tja - jeg er halvt ærgerlig over at den ikke lige tager en tur længere ned
har suppleret på vejen og mest i går. Var nok for forsigtig, idet jeg havde besluttet at næste supplering skulle være i Bull. Så halvt øv idag. Jeg er fuldkommen fast i troen på at aktien er et superkøb i disse niveauer. Blot mit pip. Men alt kan ske 
så god
stemning her
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind